Description
AIDS cholangiopathy is a form of biliary tract disease seen in patients with advanced HIV infection, specifically those with low CD4 counts (usually below 200 cells/µL). It is characterised by papillary stenosis and sclerosing cholangitis, which can result in recurrent abdominal pain, fever, and jaundice.
Pathogenesis
AIDS cholangiopathy arises due to opportunistic infections affecting the biliary system in immunocompromised HIV patients. The most commonly implicated organisms include Cryptosporidium parvum, Microsporidia, and Cytomegalovirus (CMV), though bacterial infections can also be a cause.
Epidemiology, Risk Factors & Associations
The exact prevalence of AIDS cholangiopathy is unknown but it is considered a rare complication of advanced HIV infection, typically seen when CD4 counts drop below 200 cells/µL. A higher risk has been noted in individuals with high viral loads and those not on antiretroviral therapy (ART).
Clinical Features
Patients with AIDS cholangiopathy typically present with right upper quadrant abdominal pain, fever, and jaundice, reflecting the cholestatic nature of the condition. Other symptoms may include nausea, vomiting, and weight loss.
Complications
Complications of AIDS cholangiopathy include recurrent bacterial cholangitis due to biliary obstruction, sepsis, and potentially, biliary cirrhosis and liver failure over time.
Pathological Features
Histopathology
- Macroscopic: Thickened bile ducts, with narrowed segments and possible papillary stenosis
- Microscopic: Periductal inflammation, lymphocytic infiltrates, periductal fibrosis, epithelial ulceration, presence of opportunistic organisms (e.g. Cryptosporidium)
Serology
- Raised ALP and GGT; mild to moderate transaminase elevation
Biochemistry
- Cholestatic liver enzyme pattern • Bilirubin may be mildly elevated
Immunohistochemistry
- CMV and other pathogens can be confirmed via specific antibodies if biopsy obtained
Molecular
- PCR can detect CMV, Cryptosporidium, or Microsporidia DNA from bile or biopsy specimens
Genetics
- No known genetic predisposition
Radiological Feature
General Features
- First-line: Ultrasound
- Gold-standard: MRCP or ERCP
- Imaging shows intrahepatic and/or extrahepatic bile duct strictures, often with irregular walls or beaded appearance
- Associated findings: papillary stenosis, gallbladder wall thickening, dilated CBD
CT
- Non-contrast: May show ductal dilatation
- C+ Arterial/Venous: Enhancement of thickened duct walls, periductal inflammation
ERCP
- Distal common bile duct stenosis and dilatation.
- Irregularities and strictures in intrahepatic bile ducts.
- Papillary stenosis can also be seen.
MRCP
- May show findings similar to ERCP with biliary tree irregularities.
- Distal bile duct stenosis and dilatation can also be demonstrated.
Ultrasound
- Dilation of the common bile duct and intrahepatic ducts may be seen.
Grading and Staging
There is no specific grading or staging system for AIDS cholangiopathy. Severity is usually assessed based on clinical features, degree of cholestasis, and the extent of biliary system involvement on imaging.
Differential Diagnosis
Image-based
- Primary Sclerosing Cholangitis: More common in young males with IBD; usually not associated with opportunistic infections; slower progression
• Cholangiocarcinoma: Irregular strictures, enhancing mass, elevated CA 19-9
• IgG4 cholangiopathy: Associated with autoimmune pancreatitis; elevated IgG4 levels; responds to steroids
• Post-transplant cholangiopathy: In post-liver transplant setting
• Ischaemic cholangiopathy: Especially post-transplant or shock liver; biliary necrosis
Clinically-based
• Acute cholangitis from gallstones
• Drug-induced liver injury (e.g. from antiretrovirals)
• Viral hepatitis
• Tuberculosis or fungal infections of the hepatobiliary system
Management
Management of AIDS cholangiopathy is primarily supportive, aiming to control symptoms and treat the underlying opportunistic infections. Antimicrobial therapy specific to the identified organism is key, while antiretroviral therapy is crucial for improving immune function. For symptomatic relief, endoscopic sphincterotomy or stent placement may be employed to alleviate biliary obstruction.